EA201171207A1 - Биодоступные композиции аморфного альфа-(n-сульфонамидо)ацетамидного соединения - Google Patents

Биодоступные композиции аморфного альфа-(n-сульфонамидо)ацетамидного соединения

Info

Publication number
EA201171207A1
EA201171207A1 EA201171207A EA201171207A EA201171207A1 EA 201171207 A1 EA201171207 A1 EA 201171207A1 EA 201171207 A EA201171207 A EA 201171207A EA 201171207 A EA201171207 A EA 201171207A EA 201171207 A1 EA201171207 A1 EA 201171207A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sulfonamido
bio
acetamide compound
compositions
amorphous alpha
Prior art date
Application number
EA201171207A
Other languages
English (en)
Russian (ru)
Inventor
Руйлинг Ф. Хартли
Раджа М. Хаддадин
Фэн Цянь
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201171207A1 publication Critical patent/EA201171207A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA201171207A 2009-04-14 2010-04-12 Биодоступные композиции аморфного альфа-(n-сульфонамидо)ацетамидного соединения EA201171207A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16906609P 2009-04-14 2009-04-14
PCT/US2010/030679 WO2010120662A2 (en) 2009-04-14 2010-04-12 Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
EA201171207A1 true EA201171207A1 (ru) 2012-03-30

Family

ID=42664672

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171207A EA201171207A1 (ru) 2009-04-14 2010-04-12 Биодоступные композиции аморфного альфа-(n-сульфонамидо)ацетамидного соединения

Country Status (21)

Country Link
US (1) US20100261768A1 (enExample)
EP (1) EP2419086B1 (enExample)
JP (1) JP2012524090A (enExample)
KR (1) KR20120027142A (enExample)
CN (1) CN102387788B (enExample)
AR (1) AR076306A1 (enExample)
AU (1) AU2010236701A1 (enExample)
BR (1) BRPI1012523A2 (enExample)
CA (1) CA2758709A1 (enExample)
DK (1) DK2419086T3 (enExample)
EA (1) EA201171207A1 (enExample)
ES (1) ES2426403T3 (enExample)
HR (1) HRP20130807T1 (enExample)
MX (1) MX2011010513A (enExample)
NZ (1) NZ595411A (enExample)
PL (1) PL2419086T3 (enExample)
PT (1) PT2419086E (enExample)
SI (1) SI2419086T1 (enExample)
SM (1) SMT201300106B (enExample)
TW (1) TW201043269A (enExample)
WO (1) WO2010120662A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
AR087277A1 (es) * 2011-07-21 2014-03-12 Bristol Myers Squibb Co Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3999007A (en) * 1975-10-09 1976-12-21 Carl Joseph Crane Aircraft visual approach/landing reproducer device and system
US5136301A (en) * 1989-08-30 1992-08-04 Rockwell International Corporation Primary flight display system having a vertical linear altimeter
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
DE69606804T2 (de) * 1995-06-20 2000-06-15 Honeywell, Inc. Integriertes System zur Grundkollisionsvermeidung
US5977141A (en) * 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
US6233522B1 (en) * 1998-07-06 2001-05-15 Alliedsignal Inc. Aircraft position validation using radar and digital terrain elevation database
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6570531B1 (en) * 2000-04-27 2003-05-27 Rockwell Collins, Inc. Satellite navigation receiver designed for compatibility with aircraft automatic landing systems
US6483454B1 (en) * 2000-11-28 2002-11-19 Bae Systems Aerospace Inc. Close formation aircraft collision avoidance
CN1289469C (zh) * 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
CN101274926A (zh) * 2003-03-31 2008-10-01 惠氏公司 β淀粉样蛋白生成抑制剂含氟和三氟烷基杂环磺酰胺及其衍生物
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
FR2870605B1 (fr) * 2004-05-18 2010-10-08 Airbus France Procede et dispositif de guidage automatique d'un aeronef, pour un vol au moins en partie a basse altitude
FR2880456B1 (fr) * 2005-01-03 2007-02-23 Airbus France Sas Procede et dispositif d'alerte sonore lors de la desactivation d'un pilote automatique d'un aeronef
FR2886439B1 (fr) * 2005-05-24 2010-11-05 Eurocopter France Procede et dispositif d'aide au pilotage d'un aeronef a basse altitude
CN101384250A (zh) * 2005-11-09 2009-03-11 诺瓦提斯公司 利用临时增塑剂制备药物组合物的方法
FR2897448B1 (fr) * 2006-02-14 2008-03-14 Airbus France Sas Procede et systeme d'aide au pilotage d'un aeronef.
JP2009528281A (ja) * 2006-02-17 2009-08-06 ワイス スルホンアミド置換アルコールおよびその中間体の調製方法
TW200732295A (en) * 2006-02-17 2007-09-01 Wyeth Corp Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
WO2007109604A2 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US20070218012A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
FR2911988B1 (fr) * 2007-01-26 2016-03-25 Airbus France Procede et dispositif pour determiner une hauteur maximale de stabilisation lors de la phase finale de vol d'un avion
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Also Published As

Publication number Publication date
MX2011010513A (es) 2011-11-29
PL2419086T3 (pl) 2013-11-29
ES2426403T3 (es) 2013-10-23
WO2010120662A3 (en) 2011-09-15
EP2419086B1 (en) 2013-06-26
DK2419086T3 (da) 2013-09-30
CN102387788B (zh) 2013-07-10
PT2419086E (pt) 2013-09-04
TW201043269A (en) 2010-12-16
AU2010236701A1 (en) 2011-10-20
US20100261768A1 (en) 2010-10-14
SMT201300106B (it) 2013-11-08
SI2419086T1 (sl) 2013-10-30
BRPI1012523A2 (pt) 2016-03-29
EP2419086A2 (en) 2012-02-22
KR20120027142A (ko) 2012-03-21
CN102387788A (zh) 2012-03-21
AR076306A1 (es) 2011-06-01
NZ595411A (en) 2013-02-22
HRP20130807T1 (hr) 2013-09-30
CA2758709A1 (en) 2010-10-21
JP2012524090A (ja) 2012-10-11
WO2010120662A2 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
EA201171207A1 (ru) Биодоступные композиции аморфного альфа-(n-сульфонамидо)ацетамидного соединения
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA201290255A1 (ru) Способы и композиции для лечения рака
EP2657333A4 (en) PIG CIRCOVIRUS OF TYPE 2, IMMUNA COMPOSITION THEREOF, TESTKIT AND USE THEREOF
TW200708511A (en) Novel thiophene derivatives
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BRPI0810552A2 (pt) Composição de substância ativa, processos para preparar uma composição de substância ativa, e para preparar sementes contenda substância ativa, uso da composição de substância ativa, sementes, e, composição aquosa.
TW200716552A (en) Novel thiophene derivatives
MX2011010514A (es) Composiciones de capsulas biodisponibles de compuesto amorfo alfa-(n-sulfonamido)acetamida.
BRPI0615900A2 (pt) granulados de enzima, uso de um granulado de enzima, e, ração
NI201000052A (es) Composición de zibotentan que contiene manitol y/o celulosa microcristalina.
DK1957656T3 (da) Fermentativ fremstilling af lysin
WO2010055119A3 (en) Pharmaceutical composition comprising pimobendan
DK1720550T3 (da) Derivater af piperidinylalkylcarbamater, fremstilling heraf samt anvendelse heraf som inhibitorer for FAAH enzym
EA200900942A1 (ru) Гербицидная композиция
CL2011003138A1 (es) N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion.
EA200801414A1 (ru) Кальцилитические соединения
WO2009132119A3 (en) Substituted oxazolidinones
BRPI0912551A2 (pt) compostos para tingimento de queratina, composições para tingimento de queratina contendo os ditos compopstos, e uso dos mesmos
CL2008002058A1 (es) Metodo para la preparacion de trifluoralquil-fenil-sulfonamidas y de sulfonamidas heterociclicas usando n-trifluoroacteilmorfolina; su metodo de preparacion y su uso.
NO20080053L (no) Etanolaminsalt av N-(3-metoksy-5-metylpyrazin-2yl)-2-(4-(1,3,4-oksadiazol-2-yl)fenyl)pyridin-3-sulfonamid
DK1848394T3 (da) Fremstilling af doseringsformer af smeltemasser, der indeholder aktive bestanddele
EP2324060A4 (en) ANTIBODIES AGAINST ANTI-EXTENDED TYPE I GLYCOSPHINGOLIPIDE, DERIVATIVES THEREOF AND USE
CL2007002817A1 (es) Modificacion cristalina del compuesto 4-{[(6-cloropirid-3-il)metil](metil)amino}furano-2(5h)-ona; composicion; uso de dicho compuesto; y procedimiento para combatir insectos indeseados.